Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression

Cancer Research

Volumn 62, Issue 2, 2002, Pages 450-458

  Zhang, Bin ^a   Fenton, Robert G ^a   Prendergast, George C ^b  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^b DuPont Pharmaceuticals Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; FAS ANTIGEN; GAMMA INTERFERON; LB 42722; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHO FACTOR; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING; TUMOR GROWTH;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL LINE, TRANSFORMED; CELL MEMBRANE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FIBROBLASTS; G1 PHASE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; MICE; MICE, INBRED C3H; RAS PROTEINS; RHOB GTP-BINDING PROTEIN; RNA, MESSENGER; UP-REGULATION;

EID: 0037081268     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Control of c-myc regulation in normal and neoplastic cells
2. Ras oncogenes in human cancer: A review
3. The retinoblastoma protein and cell cycle control
4. p53, the cellular gatekeeper for growth and division
5. Bcl-2 family proteins
6. Inducing autoimmune disease to treat cancer
7. General mechanisms of metastasis
8. Ras signalling and apoptosis
9. Mitogen-activated protein kinases: Specific messages from ubiquitous messengers
10. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
11. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain
12. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway
13. Myc and Ras collaborate in inducing accumulation of active cyclin F/Cdk2 and E2F
14. PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond
15. Regulation of cell death protease caspase-9 by phosphorylation
16. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
17. An essential role for NF-κB in preventing TNF-αinduced cell death
18. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
19. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras
20. An essential role for Rac in Ras transformation
21. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
22. Mutant ras oncogenes up-regulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
23. Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras
24. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
25. Apoptosis by death factor
26. A novel protein that interacts with the death domain of Fas/APOI contains a sequence motif related to the death domain
27. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
28. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
29. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
30. Discovering novel chemotherapeutic drugs for the third millennium
31. New insights into the interaction of Ras with the plasma membrane
32. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
33. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
34. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
35. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity
36. Comparison of potential markers of farnesyltransferase inhibition
37. Isoprenylation is required for the processing of the lamin A precursor
38. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A Phase I clinical-laboratory correlative trial
39. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
40. Minimal Ras-binding domain of Rafl can be used as an activation-specific probe for Ras
41. The TRAIL to selective tumor death
42. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
43. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia
44. Role of the histone deacetylase complex in acute promyelocytic leukaemia
45. Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells
46. Non-ras targets of farnesyltransferase inhibitors: Focus on Rho
47. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system
48. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-κB p50-p65 recruitment
49. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation
50. Histone acetylation and transcriptional regulatory mechanisms
51. Co-activators and co-repressors in the integration of transcriptional responses
52. Net, a negative Ras switchable TCF, contains a second inhibition domain the CID, that mediates repression through interactions with CtBP and de-acetylation
53. The "dark side" of chromatin remodeling: Repressive effects on transcription
54. Regulation of glutl mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia
55. MAP kinases and hypoxia in the control of VEGF expression
56. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
57. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis
58. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
59. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
60. Induction of apoptosis by cancer chemotherapy
61. 5-Fluorouracil induced Fas up-regulation associated with apoptosis in liver metastases of colorectal cancer patients
62. Thymineless death in colon carcinoma cells is mediated via fas signaling
63. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells